Table 2.
Distribution of Therapies for Metastatic Castration-Resistant Prostate Cancer
| Data set 1 (N = 2593) | Data set 2 (N = 626) | |||
|---|---|---|---|---|
| Therapy | First treatment, N (%) | All treatments, N (%) | First treatment, N (%) | All treatments, N (%) |
| Chemotherapy | 926 (35.7) | 1345 (51.9) | 198 (31.6) | 309 (49.4) |
| Docetaxel | 653 (25.2) | 1067 (41.1) | 127 (20.3) | 235 (37.5) |
| Carboplatin | 52 (2.0) | 146 (5.6) | 14 (2.2) | 41 (6.5) |
| Estramustine | 31 (1.2) | 107 (4.1) | 9 (1.4) | 24 (3.8) |
| Mitoxantrone | 28 (1.1) | 262 (10.1) | 7 (1.1) | 43 (6.9) |
| Cyclophosphamide | 23 (0.9) | 96 (3.7) | 6 (1.0) | 15 (2.4) |
| Secondary hormonal therapy | 1340 (51.7) | 1496 (57.7) | 350 (55.9) | 391 (62.5) |
| Antiandrogena | 1060 (40.9) | 1193 (46.0) | 288 (46.0) | 319 (51.0) |
| Bicalutamide | 961 (37.1) | 1076 (41.5) | 255 (40.7) | 282 (45.0) |
| Flutamide | 48 (1.9) | 88 (3.4) | 17 (2.7) | 25 (4.0) |
| Nilutamide | 51 (2.0) | 124 (4.8) | 16 (2.6) | 32 (5.1) |
| Adrenal androgen blocker | 261 (10.1) | 507 (19.6) | 60 (9.6) | 119 (19.0) |
| Ketoconazole | 259 (10.0) | 506 (19.5) | 60 (9.6) | 119 (19.0) |
| Aminoglutethimide | 2 (0.1) | 3 (0.1) | 0 (0.0) | 0 (0.0) |
| Estrogens | 19 (0.7) | 53 (2.0) | 2 (0.3) | 8 (1.3) |
| Diethylstilbestrol | 3 (0.1) | 13 (0.5) | 0 (0.0) | 0 (0.0) |
| Conjugated estrogens | 5 (0.2) | 10 (0.4) | 1 (0.2) | 4 (0.6) |
| Other estrogens | 11 (0.4) | 30 (1.2) | 1 (0.2) | 4 (0.6) |
| None of the above | 327 (12.6) | 327 (12.6) | 78 (12.5) | 78 (12.5) |
a
Antiandrogens initiated within 90 days before or after the initiation of luteinizing hormone-releasing hormone were not considered as a castration-resistant prostate cancer therapy.